Literature DB >> 27889668

Drug-protein binding of Danhong injection and the potential influence of drug combination with aspirin: Insight by ultrafiltration LC-MS and molecular modeling.

Junfeng Zhu1, Xiaojiao Yi1, Peng Huang1, Shuqing Chen1, Yongjiang Wu2.   

Abstract

Danhong injection (DHI) is a widely used Chinese medicine injection (CMI) for the clinical treatment of cardiovascular and cerebrovascular diseases. In this study, a simple and efficient in vitro method based on ultrafiltration LC-MS and molecular modeling has been developed to study the human serum albumin (HSA) binding of the compounds in DHI. Seven major components including protocatechuic aldehyde, p-coumaric acid, salvianolic acid D, rosmarinic acid, salvianolic acid E, lithospermic acid and salvianolic acid B were identified as HSA ligands and their binding degrees in the proposed non-saturated model were 26.17, 37.69, 99.77, 91.78, 96.91, 99.42 and 98.10%, respectively. Considering the drug-HSA binding property of the compounds in DHI may change during drug combination therapy, competitive binding assay was carried out to evaluate the influence of aspirin on the DHI-HSA binding. Experimental results revealed that the salvianolic acids in DHI had stronger binding ability to HSA than sodium salicylate. To further verify the results above, molecular modeling and probe displacement assay were conducted to investigate the optimum binding site and binding affinity of the ligands on HSA. Our findings suggested that the established method could be a powerful tool to study the drug-HSA binding property of CMIs.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aspirin; Danhong injection; Drug-protein binding; Human serum albumin; Molecular modeling; Ultrafiltration LC–MS

Mesh:

Substances:

Year:  2016        PMID: 27889668     DOI: 10.1016/j.jpba.2016.11.028

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  6 in total

1.  DanHong injection targets endothelin receptor type B and angiotensin II receptor type 1 in protection against cardiac hypertrophy.

Authors:  Min-Yu Zhang; Fei-Fei Guo; Hong-Wei Wu; Yang-Yang Yu; Jun-Ying Wei; Shi-Feng Wang; Yu-Xin Zhang; Ming-Hua Xian; Qing-Hua Wu; Bu-Chang Zhao; Shi-You Li; Hong-Jun Yang
Journal:  Oncotarget       Date:  2017-10-13

2.  Enzyme-Site Blocking Combined with Optimization of Molecular Docking for Efficient Discovery of Potential Tyrosinase Specific Inhibitors from Puerariae lobatae Radix.

Authors:  Haichun Liu; Yitian Zhu; Ting Wang; Jin Qi; Xuming Liu
Journal:  Molecules       Date:  2018-10-11       Impact factor: 4.411

3.  Systems Pharmacology-Based Approach to Comparatively Study the Independent and Synergistic Mechanisms of Danhong Injection and Naoxintong Capsule in Ischemic Stroke Treatment.

Authors:  Junfeng Zhu; Xiaojiao Yi; Yiwen Zhang; Zongfu Pan; Like Zhong; Ping Huang
Journal:  Evid Based Complement Alternat Med       Date:  2019-02-04       Impact factor: 2.629

4.  Spectrum-Effect Relationship-Based Strategy Combined with Molecular Docking to Explore Bioactive Flavonoids from Sceptridium ternatum.

Authors:  Junfeng Zhu; Haiying Ding; Like Zhong; Wenxiu Xin; Xiaojiao Yi; Luo Fang
Journal:  Molecules       Date:  2022-09-04       Impact factor: 4.927

5.  Danhong injection attenuates doxorubicin-induced cardiotoxicity in rats via suppression of apoptosis: network pharmacology analysis and experimental validation.

Authors:  Xiaojiao Yi; Fugen Wang; Yan Feng; Junfeng Zhu; Yongjiang Wu
Journal:  Front Pharmacol       Date:  2022-08-22       Impact factor: 5.988

6.  Rapid Investigation and Screening of Bioactive Components in Simo Decoction via LC-Q-TOF-MS and UF-HPLC-MD Methods.

Authors:  Yingjie He; Pi Cheng; Wei Wang; Sien Yan; Qi Tang; Dongbo Liu; Hongqi Xie
Journal:  Molecules       Date:  2018-07-20       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.